Referral pattern of pregnant mother for fetal echocardiography in Shiraz, South Iran Authors: Hamid Amoozgar, Paniz Sadeghi, Mohammadreza Edraki, Nima Mehdizadegan, Hamid Mohammadi, Amir Naghshzan Published: 2024 ABSTRACT AbstractObjectiveTo evaluate the referral patterns for fetal echocardiography at a tertiary care center in Shiraz, South Iran.MethodThis retrospective cohort study analyzed data from 22,600 pregnant women who underwent fetal echocardiography between January 1, 2016, and December 31, 2021. Information was extracted from a centralized electronic medical record system used by medical centers affiliated with Shiraz University of Medical Sciences.ResultCongenital heart disease was detected in 14.5% of fetal echocardiograms. The mean gestational age at the time of examination was 21.8 ± 4.2 weeks (range: 13–40 weeks). Notably, 75.9% of pregnant women were referred after 19 weeks of gestation. The most common reason for referral was abnormal fetal laboratory screening (triple or quad test).ConclusionIn our center, fetal echocardiography is optimally performed by 19 weeks of gestation. This timing allows for detailed anatomical assessment and aligns with the legal threshold for abortion, ensuring timely counseling and decision-making when necessary. However, in our study, the mean gestational age at the time of echocardiography was 21 weeks, indicating that a significant proportion of patients underwent the procedure later than the optimal timing.Keywords: Fetus, Echocardiography, Pregnancy Introduction Congenital heart disease (CHD) is a highly prevalent disease among infants and the leading cause of infantile mortality among congenital abnormalities [1]. The incidence of CHD in live births is about 0.4 to 1.2% [2–4]. This figure is higher among fetuses because some of them will not survive. Prenatal screening obstetric ultrasonography can easily miss structural and functional cardiac abnormalities [5]. Fetal echocardiography is a diagnostic tool for detecting heart problems during fetal life. Detecting CHD before birth may affect survival rate, morbidity, mortality, and postnatal complications [6]. Indications of fetal echocardiography are categorized into three groups by American Heart Association (AHA): familial, maternal, and fetal indications [7]. As AHA stated, some indications are: infection (for example, rubella), positive family history of CHD, abnormal cardiac screening in obstetric ultrasound, fetal dysrhythmia, abnormality of ductus venous, extracardiac malformations, known or suspected chromosomal abnormality, multiple pregnancies, maternal diabetes mellitus, maternal autoimmune disease and assisted reproductive technology. This study investigated the prevalence, referral reasons, and timing of referrals in the Shiraz-affiliated referral centers. Methods This retrospective cohort study analyzed electronic medical records of pregnant women referred to medical centers affiliated with Shiraz University of Medical Sciences, Shiraz, Iran, from January 1, 2016 to December 31, 2021. The study was conducted at tertiary care centers affiliated with Shiraz University of Medical Sciences, which serve as referral centers for high-risk pregnancies in South Iran. All pregnant women who underwent fetal echocardiography at the participating centers during the study period were included. There were no exclusion criteria. Data were extracted from a centralized electronic medical record system used by all participating centers. The database includes standardized forms for fetal echocardiography reports, which are completed by pediatric cardiologists at the time of examination. The following variables were collected: Maternal characteristics: age, gravidity, parity, number of previous abortions. Maternal characteristics: age, gravidity, parity, number of previous abortions. Gestational age at the time of fetal echocardiography. Gestational age at the time of fetal echocardiography. Indication for fetal echocardiography (chosen from a predefined list or entered as free text). Indication for fetal echocardiography (chosen from a predefined list or entered as free text). Echocardiography findings. Echocardiography findings. Recommended management plan. Recommended management plan. Indications for fetal echocardiography in our local setting include: Abnormal fetal laboratory screening (triple or quad test). Abnormal fetal laboratory screening (triple or quad test). Increased nuchal thickness. Increased nuchal thickness. Maternal diabetes mellitus. Maternal diabetes mellitus. Autoimmune disease (Anti Ro/La positive). Autoimmune disease (Anti Ro/La positive). Assisted conception. Assisted conception. Previous child with CHD. Previous child with CHD. Major extracardiac abnormality. Major extracardiac abnormality. Family history of CHD. Family history of CHD. Abnormal obstetric ultrasound findings. Abnormal obstetric ultrasound findings. Advanced maternal age (≥ 35 years). Advanced maternal age (≥ 35 years). Fetal echocardiography examinations were performed by pediatric cardiologists with expertise in fetal cardiac imaging. Our local protocol for fetal echocardiography is as follows: Initial examination between 17 and 18 weeks gestation for most indications. Initial examination between 17 and 18 weeks gestation for most indications. Earlier examination (13–16 weeks) for high-risk cases (e.g., previous child with CHD, maternal autoimmune disease). Earlier examination (13–16 weeks) for high-risk cases (e.g., previous child with CHD, maternal autoimmune disease). Follow-up examinations as needed based on initial findings. Follow-up examinations as needed based on initial findings. Final examination in the third trimester (32–36 weeks) for confirmed cardiac anomalies. Final examination in the third trimester (32–36 weeks) for confirmed cardiac anomalies. Recommendations for legal abortion were based on a combination of factors, including severity of cardiac defects, associated extracardiac anomalies, and gestational age, in accordance with Iranian law. These decisions were made by a multidisciplinary team including pediatric cardiologists, maternal-fetal medicine specialists, and medical ethicists. Our center follows the national guidelines for prenatal genetic screening and testing, which include: First-trimester combined screening (11–13 weeks): nuchal translucency measurement and serum markers (PAPP-A, free β-hCG). First-trimester combined screening (11–13 weeks): nuchal translucency measurement and serum markers (PAPP-A, free β-hCG). Second-trimester quadruple screening (15–20 weeks): AFP, hCG, uE3, inhibin A. Second-trimester quadruple screening (15–20 weeks): AFP, hCG, uE3, inhibin A. Non-invasive prenatal testing (NIPT) offered to high-risk patients. Non-invasive prenatal testing (NIPT) offered to high-risk patients. Invasive testing (CVS or amniocentesis) offered based on screening results or other risk factors. Invasive testing (CVS or amniocentesis) offered based on screening results or other risk factors. Data were analyzed using SPSS version 26.0. Descriptive statistics were calculated for all variables. Continuous data were expressed as mean ± standard deviation. Correlations between variables were assessed using Pearson’s correlation coefficient. Independent t-tests were used to compare means between groups. Logistic regression was employed to assess relationships between risk factors and abnormal echocardiography findings. Chi-squared tests were used for categorical data comparisons. A p-value < 0.05 was considered statistically significant. The study protocol was reviewed and approved by the institutional ethics committee of Shiraz University of Medical Sciences (approval number: IR.SUMS.MED.REC.1400.471). The need for individual informed consent was waived by the ethics committee due to the retrospective nature of the study and the use of de-identified data. Results Out of 22,600 pregnant women who were assessed by fetal echocardiography, the mean age of pregnant women was 31 ± 5.73 years old, and the mean gestational age (GA) at the time of fetal echocardiography was 21.86 ± 4.29 weeks. Abnormal echocardiography results were detected in 3277 (14.5%) fetuses. In 5446 (24.1%) cases, GA was below 19 weeks, and 125 (2.3%) of these fetuses had abnormal findings. Eighty-seven (1.6%) of these patients were recommended for abortion. Among echocardiograms that were done after 19 weeks of GA, 2435 (14.2%) fetuses had abnormal findings. In this group, only 0.1% were recommended for abortion. There was a statistically significant difference between these two groups (p = 0.001). The mean gravidity, parity, and abortions in the studied mothers were 2.17 ± 1.21, 1.21 ± 0.89, and 0.68 ± 0.89, respectively. The mother was older than 35 years in 6441 (28.5%) patients. Among this group, the mean GA of fetal echocardiogram was 21.59 ± 4.17, the abnormal echocardiogram was reported in 15.3%, and 0.6% were recommended for abortion. Among the studied population, the most common reasons for referral were abnormal fetal laboratory screening (triple or quad test) (33.3%), increased nuchal thickness (NT) (16.5%), and maternal diabetes mellitus (DM) (12.7%). The reasons for the referral are shown in Table 1. Table 1Cause of referral for fetal echocardiographyCauses of referralpercentAbnormal fetal laboratory screening (triple or quad test)33.3Increased Nuchal thickness16.5Maternal diabetes mellitus12.7Assisted conception12.1Previous child with CHD7.5Abnormal fetal cardiac screening6.0Autoimmune Disease: Anti-Ro/SSA and/or anti-La/SSB antibodies positive3.4Major extra cardiac abnormality3.1Fetal dysrhythmia2.0Family History of Congenital heart disease1.9Teratogenic drug (e.g. Anticonvulsant, Antidepressant intake)0.6Abnormal Fetal karyotype0.4Abnormal ductus venous0.3Multiple pregnancies (risk of TTTS)0.2Total100.0 Cause of referral for fetal echocardiography In 2.5% of mothers, more than one echocardiography was performed; among them, 50.9% had an abnormal finding. Between the cases with abnormal results, the first three indications of referral were abnormal fetal cardiac screening (21.5%), maternal DM (21.3%), and autoimmune disease (anti-Rho/La positive) (13.2%). There were 1248 diabetic mothers among the studied population; the mean age of mothers was 33.12 ± 5.40 [8–40], and the mean gestational age of referral for fetal echocardiography was 23.54 ± 5.43 [8–30, 41–45] weeks that 1010 (81%) was referred ≥ 19 weeks, GA of referred diabetic mothers are shown in Table 2. Among this group, 38.3% of mothers had no history of abortion since the last pregnancy. 126 cases (10.1%) in this group had more than one echocardiography, and the mean gestational age difference was 8.29 ± 4.23. Among this group, 338 (27.6%) had abnormal echocardiography results. Table 2Gestational age of referral in the fetus Documented risk factorsGA of referralIncreased Nuchal ThicknessAutoimmune DiseaseDiabetic Mothers< 18 weeks5.814.02.318–2384.461.553.323–287.413.419.528–321.57.812.532–360.63.19.138–400.20.33.2Total100.0100.0100.0 Gestational age of referral in the fetus Documented risk factors The mean gestational age of non-diabetic pregnant women was 20.70 ± 3.5, significantly differing from diabetic mothers (P < 0.001). The mean mother age of non-diabetic pregnant women was 31.32 ± 5.77, significantly different from diabetic mothers (P < 0.001). The mean number of previous abortions was 0.95 ± 1.04 in diabetic mothers and 0.76 ± 0.91 in non-diabetics, which showed a significant difference (P < 0.001). Our study showed a statistically significant correlation between maternal diabetes and abnormal fetal echocardiographic outcome (p < 0.001). Having diabetes increases the chance of an abnormal echocardiogram 2.1 times. Three hundred thirty-six mothers had positive extractable nuclear antigen antibodies (ENA) (anti-Ro/La positive). In this group, the mean age was 31.74 ± 4.61years, the mean gestational age was 20.83 ± 4.24 weeks, and 196 (58.4%) were referred ≥ 19 weeks (GA of referral is seen in Table 2). The number of abnormal echocardiograms was 214 (63.7%). The mean number of previous abortions was 1.15 ± 1.16, and 66.9% of mothers had a history of abortion since the last pregnancy. One-hundred seventy-two cases of this group (51.2%) had more than one echocardiography. The mean gestational age of anti-Ro/La negative pregnant women was 20.97 ± 3.86, significantly different from positive patients (P = 0.002). The mean mother age of anti-Ro/La negative pregnant women was 31.48 ± 5.79 without a significant difference from positive patients (P = 0.45). The mean number of previous abortions was 0.76 ± 0.92 in this group, which showed a significant difference with positive ENA cases (p < 0.001). A statistically significant relationship between ENA positivity and abnormal fetal echocardiography outcome (p < 0.001) was detected. Positive ENA increases the chance of abnormal echocardiogram 10.1 times. There were 1616 patients with increased NT; the mean age of mothers was 29.95 ± 5.39, the mean gestational age was 19.63 ± 2.54 (13–37) weeks, and 52.5% were referred ≥ 19 weeks (GA of referral is seen in Table 2). The abnormal result was seen in 5.6%. In increased NT patients, 1.2% have been recommended to abort. The mean gestational age of pregnant women with normal NT was 21.16 ± 3.98, mean mother age of pregnant women with normal NT was 31.69 ± 5.78, significantly different from the patients with increased NT (p < 0.001). The mean number of previous abortions was 0.56 ± 0.82 in increased NT patients and 0.80 ± 0.93 in others, which showed a significant difference (p < 0.001). The mean maternal age in the group of normal echocardiogram results was 31 ± 5.76 and 31 ± 5.69 in abnormal results, without significant difference (p = 0.994). The mean gestational age in the group of normal echocardiogram results was 21.64 ± 4.04 and 23.30 ± 5.37 in abnormal results, with significant difference (p < 0.001). In our study, no significant relation was found between the history of previous abortion and the outcome of fetal echo of the last pregnancy (p = 0.101). Discussion Our center conducts approximately 15–20 fetal echocardiograms per day. To clarify, our institution serves as a major referral center of south and southwest of Iran, which explains the high case volume. In terms of deliveries, there are approximately 52,647 per year at our affiliated facilities, with a substantial proportion of patients referred from external centers. This study provides valuable insights into the referral patterns for fetal echocardiography in a large tertiary care center in South Iran. Our findings highlight several important points that have implications for clinical practice and public health policy. Firstly, the mean gestational age at the time of fetal echocardiography was 21.86 weeks, with 75.9% of examinations performed after 19 weeks gestation. While this represents an improvement compared to previous studies in Iran [14], it still indicates that a significant proportion of women are being referred later than optimal. The American Heart Association and the International Society of Ultrasound in Obstetrics and Gynecology recommend fetal echocardiography between 18 and 22 weeks for most indications, with earlier examination (13–17 weeks) for high-risk cases [7, 46]. Our findings suggest a need for continued efforts to improve timely referrals [47]. The Iranian legislature accepts legal abortions below 19 weeks of gestation for a fetus with major congenital heart diseases like hypoplastic left or right ventricle and major valvular disease and a fetus with chromosomal abnormalities like down syndrome. According to this law, the society of Iranian pediatric cardiology recommends fetal echocardiography below 19 weeks of GA. CHD has always been one of the most important issues in medical science. With the advancement of technology, fetal echocardiography has become one of the important modalities for diagnosing CHD. This modality is currently used as the first way to a detailed diagnosis of CHD prenatally. Studies have shown that its diagnostic sensitivity and specificity are acceptable [48, 49]. The prevalence of abnormal echocardiography findings in our study was 14.5%, which is consistent with reports from other tertiary centers [41, 47, 50]. This relatively high rate underscores the importance of fetal echocardiography as a screening tool in high-risk pregnancies. Interestingly, we found no significant relationship between maternal age over 35 years and the likelihood of abnormal findings, contrary to some previous studies [12, 13]. This suggests that other risk factors may be more important in our population. The incidence of CHD was 112.89 per 10.000 live birth in Tabriz, Iran and 12.30 per 1000 live births in Ahvaz, Iran [42, 43]. Hoffman et al. [44] stated that the incidence is increasing over time and the reason for the low incidence in the past was only referral of complicated cases. The reported incidence of CHD appears to be lower than the actual value because some of them cause neonatal death in the early days that cannot be detected without an autopsy, and in contrast, a group with very mild problems such as small septal defect may never be referred to a cardiologist for examination [45]. Studies of prenatal diagnosis of heart disease have shown that the incidence of CHD varies between 2.2 and 42% in different centers worldwide [8–11, 41, 47, 50]. In this study, the mean age of referred mothers was 31 years. Although several studies showed that CHD incidence increases in maternal age over 35 years [12, 13], we did not find a significant relationship. Ghiasi et al. [14] also showed delayed referral in Mashhad, Iran. Because our study showed an earlier referral compared to theirs, it can be concluded that more attention has been paid to referral time in Iran over recent years. AHA reported that the most common reason for referral for fetal echocardiography is the sonographies suspicion of cardiac abnormality [7]. The same indication was seen in some studies [10, 14, 15]. However, other studies have reported different causes at the top of the list, like previous family history [8] and echogenic cardiac foci [9]. The most common indications for referral in our study were abnormal fetal laboratory screening, increased nuchal thickness, and maternal diabetes mellitus. This differs from some studies where suspected cardiac abnormality on routine ultrasound was the leading indication [7, 10, 14, 15]. This difference may reflect variations in screening practices or the threshold for referral across different settings. The most common referral indication among fetuses with abnormal echocardiography was abnormal fetal cardiac screening in sonography screening. Diabetes can cause different cardiac problems such as myocardial hypertrophy [16, 17], diastolic dysfunction [18], structural anomalies like a ventricular septal defect, pulmonary stenosis, and transposition of the great arteries [19]. AHA suggests cardiac evaluation in 18–22 weeks and repeats in the third trimester [7]; however, Respondek et al. [20] suggest it before 18 weeks in uncontrolled diabetics. Mosaed [20] also states that the proper GA for pregestational diabetes is 16–18 and as soon as possible after a diagnosis of gestational diabetes. In different studies, the need for fetal heart examination in these mothers is different [22, 23]. In our study, the mean gestational age in diabetes was 23.5, which seems to be late. According to our results, gestational age is significantly different between diabetic mothers and other patients; which indicates more attention to the time of referral in this group. In our study, the average number of previous abortions were higher in diabetic patients than in others. Becerra et al. showed that the relative risk of CHD in infants of insulin-dependent gestational DM (GDM) mothers is 18 times more than in non-diabetic, and major cardiac defects are 20.6 times more. No significant difference was seen between non-insulin-dependent GDM and insulin-dependent mothers for major cardiac defects [24]. A study in Boston showed that CHD risk in infants of pregestational diabetic mothers was fivefold more than general population [25]. In our study, diabetes doubles the chances of developing a heart problem in the fetus regardless of the type of DM. In Lisowski’s [26] study, three different centers were studied, and the incidence of CHD in pregnant women with type 1 diabetes was from 2.5 to 6.2%. About 9% in Tabib et al. [23] and 3.1% in Wittkopf et al. [27]. Martinez et al. showed that CHD incidence in pregestational DM is 21%, 2.8 times higher than in non-diabetics (7.5%). In insulin-dependent, 30.8% had CHD, while 10.8% in non-insulin-dependent [28]. Some studies showed that fetal congenital heart disease incidence is equal between gestational and pregestational diabetic mothers [19, 24]. Our study showed 27.6% abnormal findings in diabetic fetuses, which showed a higher prevalence than in other studies. Due to the high prevalence of heart problems in diabetic patients and the 10.3% prevalence of diabetes in Iran [23], more attention should be paid to the referral and evaluation of these mothers in our region. Our study confirmed the increased risk of cardiac abnormalities in fetuses of diabetic mothers, with diabetes increasing the odds of an abnormal echocardiogram by 2.1 times. This is lower than some previous reports [24, 25] but still significant. We also found that diabetic mothers were referred later (mean 23.54 weeks) compared to non-diabetic mothers, highlighting a potential area for improvement in care. Anti-Ro/SSA and anti-La/SSB antibodies can be detected in some autoimmune diseases like Sjögren syndrome and systemic lupus erythematosus [29]. It is proven that there is an association between anti-SSA and anti-SSB antibodies and heart defects [13, 47]. Congenital heart block is due to the entry of Anti-Ro/SSA and anti-La/SSB antibodies into the fetus via the placenta and deposited in cardiac connective tissue [30, 31]. The prevalence of heart block is 1 and 5%, which may increase to 25% in the presence of an affected sibling [32–36]. However, Edgar et al. [37] showed that most cases were detected in mothers without a previous child with a heart block. Incidence in another study was 17.9% [28]. Our study showed 63.7% abnormal echo among 336 mothers with positive antibodies and an increased chance of CHD tenfold higher in this group. The risk ratio in anti-SSA mothers was 14 in Ramsey-Goldman et al. [38]. They also showed that increasing antibody titers increase the risk of heart block. Our results showed that the average number of previous abortions was higher in ENA-positive patients. The strong association between maternal anti-Ro/La antibodies and abnormal fetal echocardiography (increasing odds by 10.1 times) is particularly noteworthy. This emphasizes the importance of screening for these antibodies in pregnant women with autoimmune diseases and ensuring early fetal cardiac evaluation in positive cases. Increased NT was the second main reason for referring to fetal echocardiography. Some studies reported a correlation between NT and increased CHD risk [39, 40, 51]. Performing an echocardiogram in the first trimester by a qualified specialist can help diagnose important heart diseases [47, 52–54]. On the other hand, Rustico et al. [55] oppose this and do not find appropriate sensitivity (33%). According to studies by Sairam & Carvalho [56] and Respondek et al. [20], the study of these patients under 18 weeks is better. Carvalho et al. [57] state that the appropriate GA for screening is below 14 weeks, with a follow-up in 20–22 weeks. In our study, the mean gestational age was 19.63 weeks, and 47.5% were referred under 19 weeks. The prevalence of heart defect was 5.6 in the fetus with high NT. Clur et al. [58] showed that the prevalence of CHD can vary from 1.9 to 64%, depending on the NT size. Hyett et al. [59] showed 1.7 in 1000 pregnancies, and Fuladi et al. showed 9% [60]. Conclusion In our center, fetal echocardiography is optimally performed by 19 weeks of gestation. This timing allows for detailed anatomical assessment and aligns with the legal threshold for abortion, ensuring timely counseling and decision-making when necessary. However, in our study, the mean gestational age at the time of echocardiography was 21 weeks, indicating that a significant proportion of patients underwent the procedure later than the optimal timing. Increasing the awareness of physicians, especially gynecologists, and raising public awareness about the importance of early diagnosis of heart disease can play an essential role in improving this situation. Limitations Several limitations should be considered when interpreting the results of this study: (1) Retrospective design: As a retrospective study, our analysis was limited to the available data in medical records, which may have been incomplete or subject to documentation errors. (2) Single-center study: The study was conducted at a single tertiary care center, which may limit the generalizability of our findings to other settings or populations. (3) Missing data: The handling of missing data was not explicitly addressed in our analysis, which could potentially introduce bias. (4) Lack of long-term follow-up: Our study did not include postnatal confirmation of prenatal diagnoses or long-term outcomes of the infants. (5) Potential selection bias: As a referral center, our patient population may be skewed towards higher-risk pregnancies, potentially overestimating the prevalence of cardiac abnormalities. (6) Limited socioeconomic data: We did not collect information on socioeconomic factors that might influence access to prenatal care and timely referrals. (7) Evolving technology: Over the five-year study period, improvements in ultrasound technology may have influenced diagnostic accuracy, particularly for earlier gestational ages. Author contributions H.A. contributed to the design and implementation of the research, to the analysis of the results and to the writing of the manuscript. P.S. Data gathering, the analysis of the results and to the writing of the manuscript. M.E. The analysis of the results and to the writing of the manuscript. N.M. The analysis of the results and to the writing of the manuscript. H.M. Data gathering, the analysis of the results and to the writing of the manuscript. A.N. The analysis of the results and to the writing of the manuscript. All authors reviewed the manuscript. Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Data availability Upon request, the corresponding author can provide the data. Declarations Ethics approval and consent to participate This study protocol was reviewed and approved by the institutional ethics committee of Shiraz University of Medical Sciences (approval number: IR.SUMS.MED.REC.1400.471). Due to the retrospective nature of the study and the use of de-identified data from existing medical records, the ethics committee waived the requirement for individual informed consent from participants. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Upon request, the corresponding author can provide the data.